EOSINOPHILIC ESOPHAGITIS MARKET ANALYSIS

Eosinophilic Esophagitis MarketSize and Trends

Global eosinophilic esophagitis market is estimated to be valued at USD 237.5 Mn in 2024 and is expected to exhibit a CAGR of 33.2% during the forecast period (2024-2031). 

Figure 1. Global Eosinophilic Esophagitis Market Value (USD Mn), by Region, 2024

Promising results for potential drug candidates are estimated to drive the global eosinophilic esophagitis market growth during the forecast period.

• Drug candidates which are developed and investigated for the treatment of eosinophilic esophagitis have shown promising results in clinical trials. As a result, regulatory authorities such as the U.S. Food and Drug Administration (FDA) are awarding designations to these drug candidates. This is expected to augment the market growth over the forecast period. For instance, in February 2021, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced that the company received Fast Track designation from the U.S. FDA for the treatment of Eosinophilic Esophagitis (EoE), a rare, chronic allergic inflammatory disease characterized by eosinophilic infiltration of the esophagus.

Increasing awareness programs for Eosinophil-associated disorders is anticipated to propel the global eosinophilic esophagitis market growth over the forecast period.

Various awareness programs have been developed and implemented to educate the public and medical community about eosinophil-associated disorders which is anticipated to drive the market growth over the forecast period. The American Partnership for Eosinophilic Disorders (APFED), a nonprofit organization, was founded in December 2001, which works on educating, raising awareness, supporting, and advocating for patients and families who are suffering from eosinophil-associated diseases.